Last reviewed · How we verify
conventional-dose ticagrelor
Ticagrelor is a platelet aggregation inhibitor that works by blocking the P2Y12 receptor.
Ticagrelor is a platelet aggregation inhibitor that works by blocking the P2Y12 receptor. Used for Atrial fibrillation for stroke prevention, Acute coronary syndrome.
At a glance
| Generic name | conventional-dose ticagrelor |
|---|---|
| Sponsor | First Affiliated Hospital of Harbin Medical University |
| Drug class | P2Y12 receptor antagonist |
| Target | P2Y12 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
This action prevents platelets from aggregating and forming blood clots, which can cause heart attacks and strokes. Ticagrelor is a reversible antagonist of the P2Y12 receptor, which is a key player in platelet activation and aggregation.
Approved indications
- Atrial fibrillation for stroke prevention
- Acute coronary syndrome
Common side effects
- Bleeding
- Dyspnea
- Headache
- Nausea
- Diarrhea
Key clinical trials
- STEMI Treated With a Polymer-free Sirolimus-coated Stent and P2Y12 Inhibitor-based SAPT Versus Conventional DAPT (NA)
- TAILored Versus COnventional AntithRombotic StratEgy IntenDed for Complex HIgh-Risk PCI (PHASE4)
- Tailored Versus Coventional AntiPlaTelet Strategy Intended After OPTIMIZEd Drug Eluting Stent (PHASE4)
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
- Century Clot-Guided Prophylactic Rivaroxaban for Post STEMI Complicating Left Ventricular Thrombus (PHASE4)
- To Evaluate Whether IVUS-guided Drug-eluting Stent (DES) Implantation Leads to Better Clinical Outcomes Compared to Conventional Angiography in the Treatment of Chronic Complete Occlusion (CTO) Disease. (NA)
- The Effect of Early Administration of Dapagliflozin in STEMI Patients With LV Systolic Dysfunction (NA)
- Intravenous MSC Therapy on Ischemia-Reperfusion Injury in Patients With Myocardial Infarction (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: